Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial

BACKGROUND: Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity of PD-1 inhibitors. A potential strategy to convert a cold into an inflamed microenvironment lies on a combination therapy. As tumor angiogenesis promotes immunosuppression, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin-Broto, Javier, Hindi, Nadia, Grignani, Giovanni, Martinez-Trufero, Javier, Redondo, Andres, Valverde, Claudia, Stacchiotti, Silvia, Lopez-Pousa, Antonio, D'Ambrosio, Lorenzo, Gutierrez, Antonio, Perez-Vega, Herminia, Encinas-Tobajas, Victor, de Alava, Enrique, Collini, Paola, Peña-Chilet, Maria, Dopazo, Joaquin, Carrasco-Garcia, Irene, Lopez-Alvarez, Maria, Moura, David S, Lopez-Martin, Jose A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674086/
https://www.ncbi.nlm.nih.gov/pubmed/33203665
http://dx.doi.org/10.1136/jitc-2020-001561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674086/
https://www.ncbi.nlm.nih.gov/pubmed/33203665
http://dx.doi.org/10.1136/jitc-2020-001561

Ejemplares similares